Radiocontrast nephropathy (RCN) is a common clinical problem without effective therapy. Utilizing a murine model, we tested the hypothesis that alpha-2 adrenergic receptor agonists [clonidine, dexmedetomidine (dex)] protect against RCN, induced with iohexol (a nonionic low-osmolar radiocontrast). C57BL6 mice were pretreated with saline, clonidine, or dex before induction of RCN. Some mice were pretreated with yohimbine (a selective alpha-2 receptor antagonist) prior to saline, clonidine or dex administration. Alpha-2 agonist treated mice had reduced plasma creatinine, renal tubular necrosis, renal apoptosis, and renal cortical proximal tubule vacuolization 24 hrs after iohexol injection. Yohimbine reversed the protective effects of both clonidine and dex pretreatment. Injection of iohexol resulted in a rapid (~90 min.) fall of renal outermedullary blood flow. Clonidine and dex pretreatment significantly attenuated this perfusion decrease without any changes in systemic blood pressure. To determine whether proximal tubular alpha-2 adrenergic receptors mediate the cytoprotective effects, we treated cultured human proximal tubule (HK-2) and rat pulmonary microvascular endothelial cells (RPMEC) with iohexol after vehicle, clonidine or dex pretreatment.
Introduction
Arteriography, angiocardiography, and contrast enhanced CAT scans, account for more than 3 million iodinated radiocontrast exposures each year in the U.S. (15) . Renal dysfunction secondary to radiocontrast administration remains prevalent and debilitating (3) . Radiocontrast nephropathy (RCN) remains the third most common cause of inpatient acute renal failure behind ischemia reperfusion injury and nephrotoxic medication administration (23) . The diagnosis of RCN confers a 5.5 fold increase in hospital mortality (18, 29) , may necessitate hemodialysis (7) , and is associated with an increased hospital length of stay and incidence of myocardial infarction (25) .
Although the pathogenesis of RCN remains incompletely understood, tubular hypoxic injury, due to a reduction in renal medullary blood flow, and direct tubular cytotoxicity play a substantial role (8, 12, 31) . The risk of developing nephropathy following radiocontrast exposure may be as high as 50%, depending on numerous risk factors (21) . Pre-existing renal dysfunction and dehydration are the most predictive contributors to RCN, while volume of contrast exposure, contrast osmolality, congestive heart failure, diabetes, anemia, and advanced age also increase risk (2, 3) . Despite the exploration of numerous prophylactic regiments (N-acetylcysteine, theophylline, sodium bicarbonate, dopamine, fenoldopam, calcium channel blockers) and attempts at developing less toxic (lower osmolar) contrast agents, isotonic intravenous hydration remains the only proven RCN prophylaxis (3, 22, 30) .
Alpha-2 agonists have diuretic (26) and sympatholytic effects (20) . Having noted the corticomedullary ischemic pathogenesis of radiocontrast-induced nephropathy and the decreased systemic vascular resistance and diuretic properties of alpha-2 agonism, we hypothesized that exogenously administered alpha-2 agonists would preserve outermedullary renal blood flow and protect against renal dysfunction following iodinated radiocontrast exposure. To test this hypothesis, we utilized both in vivo and in vitro models of RCN.
Materials and Methods

Mice
Male C57BL/6 mice (25 grams) were purchased from Harlan Laboratories (Indianapolis, IN). The Columbia University Institutional Animal Care and Use Committee approved the animal care protocol for the experiments performed in this study.
Murine model of radiocontrast-induced nephropathy
Radiocontrast nephropathy (RCN) was induced in mice as described previously (16) . After overnight (16 hr) water deprivation and prior inhibition of prostaglandin and nitric oxide synthesis, mice were injected subcutaneously (SQ) with the low-osmolar monomeric iodinated radiocontrast media, iohexol (Omnipaque, 1.5 g iodine/kg). To inhibit cyclooxygenase and nitric oxide synthase, mice were injected with indomethacin 10 mg/kg SQ (dissolved in dimethylsulfoxide) and levo-nitroargininemethylester (L-NAME) 10 mg/kg SQ (dissolved in 0.9% saline), respectively, 15 minutes prior to iohexol injection. This model reliably produces nephropathy following radiocontrast injection, and has been previously validated in mice and rats (6, 16) . Animals were then given access to food and water and sacrificed 24 h later for serum creatinine determination and kidney removal. Sham mice received SQ injections of saline instead of iohexol after indomethacin and N G -nitro-L-arginine methyl ester injection and 16 hrs of water deprivation.
To determine whether alpha-2 adrenergic receptor agonist protect against murine RCN, we subjected mice to the following treatment groups: 1) saline 100μl bolus SQ plus SQ infusion at 1μl/hr, 2) 5 or 10 μg/kg bolus clonidine SQ, 3) 5 or 10 μg/kg bolus clonidine SQ plus 5 or 10μg/kg/h infusion SQ, 4) 3μg/kg bolus dex SQ, 5) 3μg/kg bolus dex SQ plus 2 or 4μg/kg/h infusion SQ. Subcutaneous infusion of drugs or saline was achieved by micro-osmotic pumps (Alzet Co., Cupertino, CA; Model 1003D; 1 μl/hr), implanted 16 hrs prior to iohexol injection. To determine whether blockade of alpha-2 receptors prevents any dex-or clonidine-mediated protection against RCN, some mice were injected with 0.1 mg/kg yohimbine (a selective alpha-2 adrenergic receptor antagonist) after miniosmotic pump placement and before bolus injection of saline, clonidine, or dex.
Assessment of nephropathy after iohexol injection
We assessed renal function 24 hr after radiocontrast injection by determining plasma creatinine concentration, using the colorimetric method based on the Jaffe reaction (11) , and by assessing kidneys for necrosis, apoptosis and cortical vacuolization (osmotic nephrosis).
For histological light microscopy preparations, we selected kidneys from six randomly selected mice from the saline RCN, clonidine (10ug/kg/h + 10ug/kg) RCN, and dex (4ug/kg/h + 3ug/kg) RCN groups, 24 hr after iohexol injection (following blood collection). Kidneys were bisected along their long axis and fixed in 10% formalin for 24 hours. Following automated dehydration through a graded alcohol series, transverse kidney specimens were imbedded in paraffin, sectioned at 5 μm, and stained with haematoxylin and eosin. An experienced renal pathologist, blinded to the animal treatment group, assessed proximal tubular necrosis, apoptosis, and cortical tubule 
Assessment of outer-medullary renal blood flow after iohexol injection
In a separate cohort of male C57BL/6 mice, outer-medullary blood flow was recorded for 90 minutes following iohexol injection in our murine model of RCN.
Systemic blood pressure was also recorded during this period by carotid artery cannulation. Outer medullary renal blood flow was quantified using laser-Doppler flow probes as described previously (1) . Laser-Doppler flow probes provide reliable measurements of relative change in regional blood flow in rodent kidney (27) . In brief, a needle flow probe (480 µm diameter; Model TSD145) connected to a laser-Doppler flowmeter (Biopac Systems, Goleta, CA) measures red blood cell volume and velocity in the cubic millimeter 1mm distal to the tip of the flow probe. Flow is derived as the product of red blood cell volume and velocity. The relative change in outer medullary blood flow before and after radiocontrast injection was measured in saline, clonidine (10μg/kg), and dexmedetomidine (3μg/kg) pretreated mice.
Following 16 hr overnight dehydration, C57BL/6 mice were anesthetized with intraperitoneal pentobarbital (i.p.) (50 mg/kg or to effect) and placed them in a heating pad to maintain body temperature between 36 and 38°C. Additional pentobarbital (10% of the original dose) was given as needed, based on tail pinch. Right carotid artery was cannulated for blood pressure measurements, and we exposed the left kidney by laparotomy. The needle tip of the flow probe was then inserted directly into the renal cortex and advanced into the outer-medulla (approximately 1.5 mm beneath the surface of the kidney). Although the insertion of the probe is invasive, blood flow is measured in the undisturbed region 1 mm beneath the tip of the optical probe. Voltage output was recorded on a computer connected to a Biopac data acquisition system and displayed as blood perfusion units. The flow data is then represented as the percent of the baseline blood flow for each mouse.
Baseline renal blood flow and systemic blood pressure were established prior to i.p. administration of saline (100μl), clonidine (10μg/kg), or dex (3μg/kg). Fifteen minutes later, indomethacin (10mg/kg) and l-NAME (10mg/kg) were injected i.p.
Iohexol (1.5g iodine/kg) was then injected i.p. 15 minutes later. Medullary blood flow and systemic blood pressure were continuously recorded for 90 minutes after iohexol injection. At the end of each experiment, the mouse was sacrificed, and the kidney removed and bisected to confirm the position of the needle probe tip in the outer medulla.
Mice with incorrectly placed probes were excluded from the study.
Cell Culture
Immortalized human proximal tubule cells (HK-2 cells, American Type Culture Collection, Manassas, VA) were grown and passaged in culture medium (50:50 mixture of low-glucose DMEM and F-12 plus 5% serum) and antibiotics (100 U/ml of penicillin G, 100 μg/ml of streptomycin, and 0.25 μg/ml of amphotericin B) at 37°C in a 100% humidified atmosphere of 5% CO 2 -95% air. Rat pulmonary microvascular endothelial cells (RPMEC) were obtained from Dr. E. Heidi Jerome (Departments of Anesthesiology and Pediatrics, Columbia University) and grown in F-12 medium plus 10% serum. Cells were plated in 24-well plates and used in the experiments described below when confluent.
In vitro models of radiocontrast nephropathy
An in vitro model of radiocontrast injury was used as described previously (13, 16) . Confluent monolayers of HK-2 cells or RPMEC were pretreated with saline, clonidine (10μM), or dex (10μM) for 30 minutes before iohexol (0, 50, 100, or 150mg/ml iodine) treatment. Following 16 hours of radiocontrast exposure, HK-2 cell viability was quantified by MTT assay.
Measurement of cell viability
Cell viability was assessed and quantified using a 3-[4,5-dimethyl(thiazol-2-yl)-3,5-diphery] tetradium bromide (MTT) cytotoxicity assay as described previously [22] .
The MTT assay measures mitochondrial dehydrogenase activity, a component of the Krebs cycle, and a marker of energy production and cellular viability. During this comparison and assessment for differences between outer-medullary renal blood flow (or systemic blood pressure) profiles in clonidine and saline treated animals (or dex and saline treated animals), fixed effects included treatment, time from radiocontrast exposure, and treatment by time interaction. To account for the correlations between repeated measurements at different time points, mice were modeled using random effect. If the treatment by time interaction was statistically significant, the two profiles differ. That is, the treatment effect differs at different time points. If the treatment by time interaction was not statistically significant, it suggests that the two profiles are parallel and the treatment effect is the same at all time points. In this case, difference in profiles is then assessed using overall effect analysis. P values less than 0.05 were considered statistically significant. We used SAS version 9.1 (SAS Institute, Cary, NC) for all statistical analyses. clonidine 10μg/kg/h + 10μg/kg; Cr=1.5+0.2, n=10, p=0.002, dex 4μg/kg/h + 3μg/kg + yohimbine 0.1mg/kg x2 vs. dex 4μg/kg/h + 3μg/kg). Moreover, these plasma creatinine concentrations were indistinguishable from saline iohexol controls (Cr=1.5+0.4, n=6, p=0.959, clonidine 10μg/kg/h + 10μg/kg + yohimbine 0.1mg/kg x2; Cr=1.5+0.2, n=10, p=0.890, dex 4μg/kg/h + 3μg/kg + yohimbine 0.1mg/kg x2). Yohimbine did not produce nephropathy when injected without iohexol (Cr=0.38+0.1, n=4, p=1.000, yohimbine sham). Yohimbine alone also did not exacerbate RCN after iohexol injection (Cr=1.6+0.2, n=5, p=0.716) compared to saline iohexol controls ( Figure 1C ).
Results
Development of radiocontrast nephropathy in mice
We performed additional in vivo studies to extend the course of radiocontrast nephropathy and examined plasma creatinine beyond 24 hrs. Six C57BL/6 mice were subjected to RCN (iohexol injection after overnight water deprivation and indomethacin and L-NAME injection) after clonidine (10 μg/kg bolus and 5 μg/kg/hr infusion) or saline treatment. Our model of un-resuscitated RCN resulted in severe renal injury with high mortality as 3 out of 6 mice in the saline-vehicle group died before reaching day #2
and an additional mouse died before reaching day #3. In contrast, only 1 mouse died before reaching day #2 and the entire remaining 5 mouse survived to day #3 in the clonidine treated group. The plasma creatinine values at day #2 and #3 were 0.67+0.03 mg/dL (N=3) and 0.47+0.1 mg/dL (N=2) for the saline group, respectively. Clonidine treatment lead to plasma creatinine values of 0.58+0.09 mg/dL (N=5) and 0.45+0.07 mg/dL (N=5) at days #2 and #3, respectively.
Plasma concentrations of clonidine and dex
The plasma concentration of clonidine at the time of iohexol injection was 0.70+0.11 ng/ml (n=5). Dex plasma concentration at the time of iohexol injection was 0.51+0.07 ng/ml (n=5).
Histological findings
Histological evaluation of kidney sections from all mouse cohorts subjected to RCN revealed cortical proximal tubular necrosis, vacuolization and apoptosis. However, when compared to RCN saline control animals, clonidine (10μg/kg bolus + 10μg/kg/h infusion) and dex (3μg/kg bolus + 4μg/kg/h infusion) pretreated animals had significantly less proximal tubular necrosis (clonidine: 1.6+0.5 necrotic tubules/400x field, n=6, p<0.034; dex: 0.5+0.4, n=6; saline: 5.7+1.6, n=6, p<0.01). Alpha-2 agonist treated animals also developed less cortical vacuolization (Figure 2 ). TUNEL staining revealed more apoptotic cells in renal cortices of iohexol exposed animals treated with saline than in animals treated with clonidine or dex (clonidine: 38+10 TUNEL positive cells/100x field, n=6, p<0.05 compared to saline; dex: 23+5, n=6 p<0.01 compared to saline; saline:
122+11, n=6, Figure 3 ).
Renal outer-medullary blood flow following radiocontrast exposure Outer-medullary renal blood flow decreased rapidly and significantly in all animals following radiocontrast injection during the 120 minute experiment. However, clonidine (10μg/kg bolus) or dex (3μg/kg bolus) pretreatment preserved renal outermedullary blood flow after radiocontrast exposure when compared to saline pretreatment.
For the clonidine cohort, the linear mixed effect model revealed a lack of interaction between pretreatment and time, and overall effect analysis demonstrated significant differences between clonidine and saline renal blood flow profiles (p=0.020). For the dex cohort, the linear mixed effect model verified significant pretreatment and time interaction, suggesting unique renal blood flow profiles for dex and saline treated mice (p=0.004). Systemic blood pressure did not change significantly throughout the 90 minutes following iohexol injection in saline, clonidine, or dex cohorts (Figure 4 ).
Radiocontrast exposure and direct renal tubular toxicity in vitro
Isolated HK-2 proximal tubule cells experienced dose-dependent reductions in viability following 16 hour exposure to 50, 100, and 150 mg iodine/ml iohexol (91 +9% viability, n=12, at 50mg/mL iodine iohexol exposure; 52 +7%, n=12, at 100mg/mL iodine iohexol exposure; 24 +7%, n=12, at 150mg/mL iodine iohexol exposure). Alpha-2 adrenergic agonist pretreatment failed to decrease the cytotoxicity secondary to iohexol exposure in HK-2 cells when compared to saline pretreatment (data not shown).
Iohexol also caused dose-dependent reductions in viability following 16 hour exposure to 50, 100, and 150 mg iodine/ml iohexol (71 +3% viability, n=6, at 50mg/mL iodine iohexol exposure; 53+3%, n=6, at 100mg/mL iodine iohexol exposure; 8+2%, n=6, at 150mg/mL iodine iohexol exposure) in RPMEC. Either of the alpha-2 adrenergic agonist pretreatments again failed to decrease the cytotoxicity secondary to iohexol exposure in vascular endothelial cells, when compared to saline pretreatment (data not shown). We chose clonidine or dexmedetomidine to activate alpha-2 adrenergic receptors.
Discussion
Both of these drugs are commonly used clinically and have proven safety profiles. Direct measurement of systemic blood pressure in mice demonstrated that the doses of clonidine and dexmedetomidine we studied do not lead to hypotension. Therefore, protective effects of clonidine and dexmedetomidine on renal cortico-medullary blood flow cannot be due to the changes in systemic blood pressure.
The plasma level measurements of clonidine (0.7 ng/ml) and dexmedetomidine (0.51 ng/ml) demonstrated that the observed preservation of medullary renal blood flow, maintenance of renal function, and reduced markers of tissue injury were achieved at concentrations commonly found in humans prescribed clonidine and dexmedetomidine.
Specifically, during the management of hypertension, effective clonidine therapy is commonly achieved at steady state plasma concentrations of 0.8ng/ml (19).
Dexmedetomidine's effects are achieved with a plasma concentration of 0.81ng/ml (5, 19) .
Differences in pharmacokinetics likely account for the discrepancy between the clonidine bolus only group, which showed both a significant reduction in plasma creatinine rise after iohexol exposure and preserved renal medullary blood flow, and the dexmedetomidine bolus only group, which showed no reduction in creatinine rise but preserved renal medullary blood flow ( Figures 1A, 1B, 4 ). Dexmedetomidine's relatively short elimination half-life of two hours (28) To better investigate the mechanisms and possible therapies for RCN, we developed a murine model of RCN. One of the limitations of this study is that our model utilizes young and healthy mice. These mice may not comprehensively mimic the infirmed patients that typically develop clinical RCN. Patients at high risk for developing RCN frequently are intravascularly dehydrated and have exhausted the cellular mechanisms that maintain medullary oxygen delivery (24) . Therefore in our murine model, we withheld water for 16 hrs prior to iohexol injection, and we inhibited prostanoid and nitric oxide synthesis. With these interventions, we were able to create a reliable and consistent model of RCN, a model that has been previously described in mice and rats (6, 12, 16) .
We attempted to extend the course of RCN in this study to examine plasma creatinine beyond 24 hrs. However, our model of un-resuscitated RCN resulted in severe renal injury leading to high mortality (50%) in less than 48 hrs for the saline-treated mice.
Although, the plasma creatinine values were similar between saline-treated and clonidine-treated mice subjected to RCN at day #2, we believe that the saline-treated mice that survived did so because they had reduced renal injury compared to the mice that died. These surviving mice, as well as their plasma creatinine values, reflect a selection bias. One of the limitations of our study is that due to the severe nature of our RCN model, we were unable to conclusively examine whether alpha-2 agonist-mediated renal protection persists beyond 24 hrs.
In summary, we have demonstrated that clonidine and dexmedetomidine attenuate the reduction in renal blood flow following radiocontrast injection and attenuate the development of subsequent nephropathy. Developing renal protective therapies remains vital to decreasing the morbidity and mortality associated with radiocontrast exposure.
Reductions in renal function following radiocontrast exposure may be permanent, and 40% of patients meeting the diagnostic criteria for RCN may require hemodialysis (21).
Whether alpha-2 agonists benefit humans subjected to the diagnostic and therapeutic procedures that utilize iodinated radiocontrast media remains to be determined.
Furthermore, whether alpha-2 adrenergic agonist mediated renal benefits surpass those of intravascular hydration alone warrants investigation.
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